查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929584

GalNAc-siRNA偶联物市场按产品类型、适应症、製剂、最终用户和分销管道划分，全球预测，2026-2032年

GalNAc-siRNA Conjugates Market by Product Type, Indication, Formulation, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

GalNAc-siRNA偶联物市场预计到2025年将达到6.7121亿美元，到2026年将成长到7.2996亿美元，到2032年将达到11.0537亿美元，复合年增长率为7.38%。

主要市场统计数据
基准年 2025 6.7121亿美元
预计年份：2026年 7.2996亿美元
预测年份：2032年 11.0537亿美元
复合年增长率 (%) 7.38%

本书以清晰权威的视角，将 GalNAc-siRNA 疗法置于不断发展的递送技术、临床检验和商业化框架下进行介绍。

GalNAc偶联的小干扰RNA (siRNA)疗法已成为针对定向基因静默的一项突破性创新，它整合了寡核苷酸化学、递送技术和临床应用框架的最新进展。过去十年，N-乙酰半乳糖胺配体的优化使得siRNA能够透过肝细胞上的Glico蛋白受体选择性摄取，与传统的全身性寡核苷酸疗法相比，显着提高了疗效和安全性。因此，GalNAc-siRNA平台现已成为治疗肝臟疾病和全身性疾病的基础治疗方法，在这些疾病中，降低致病蛋白的表达能够带来治疗益处。

从技术、临床检验和商业策略的角度，全面探讨重塑 GalNAc-siRNA 创新的关键转型转变。

由技术成熟、临床验证不断扩展以及商业模式不断演进所驱动的 GalNAc-siRNA 治疗领域正经历着一场变革性的转变。配体结构的进步正在突破单一范式，使研发人员能够精细调控价态和偶联化学，从而提高肝细胞特异性和细胞内释放效率。同时，生产技术的改进，例如可扩展的寡核苷酸合成和稳健的纯化流程，正在降低多资产开发的实际障碍，并使临床和商业批次的品质属性更加可预测。

深入分析近期美国关税调整的累积影响如何重塑开发公司的供应链韧性、采购和专案成本结构。

影响全球生物製药供应链的政策环境对研发和商业化进程的重要性日益凸显。这是因为美国近期采取的贸易行动和关税调整，给某些原材料和成品带来了额外的成本压力。 2025年关税相关政策的变化改变了寡核苷酸合成和偶联製程中使用的原料、试剂和特殊组分的采购经济性，因此企业必须迅速重新评估筹资策略并实现供应商多元化。这些变化对依赖跨境供应链的製造商产生了连锁反应，导致一些製造商加快对替代供应商的资格认证，或透过将关键生产流程转移到国内来降低风险。

关键的细分市场洞察揭示了产品结构、临床标靶、医疗环境、分销方式和製剂选择如何相互作用，从而影响产品开发和应用。

细分市场洞察揭示了产品架构、临床标靶、临床试验中心、分销管道和製剂选择等领域中科学机会与商业性需求的交汇点。在产品类型方面，研发人员正在调整价态决策，以平衡效力和下游製程的复杂性，因为二价、单价和三价偶联物之间的差异决定了受体亲和性、核内体逃脱效率和可生产性方面的权衡。在适应症方面，针对急性肝紫质症、遗传性高高胆固醇症、1型原发性草酸尿症和转甲状腺素类淀粉沉积症样变性的临床项目分别凸显了不同的研发路径。罕见遗传疾病通常需要加快监管审批和基于疗效的定价讨论，而针对更常见血脂异常症的项目则需要强有力的比较疗效证据和广泛的临床医生培训。

提供全面的区域性洞察，阐述监管、支付体系、临床试验能力和生产设施等方面的区域差异如何影响商业化策略。

区域趋势对临床开发管道、监管互动和商业性准入策略产生了深远影响，美洲、欧洲、中东和非洲以及亚太地区之间存在显着差异。在美洲，临床试验基础设施的集中、支付方的创新以及投资资本的涌现，使得后期开发得以加速，商业化模式也更加多样化，但报销谈判和区域采购实践需要严谨的卫生经济学证据和真实世界结果数据。同时，欧洲、中东和非洲的监管和支付方环境与欧洲整体监管管道存在差异，各国的卫生技术评估流程各不相同，新兴市场的准入条件也存在差异，因此需要製定量身定制的市场准入和定价策略。

公司层面的关键洞察表明，平台开发、伙伴关係模式、生产准备和监管合作是 GalNAc-siRNA 竞争格局中的差异化因素。

GalNAc-siRNA疗法研发公司之间的竞争反映了平台专业化、临床执行能力和策略联盟之间的平衡。主要企业正致力于提昇平台稳健性（优化偶联化学、增强细胞内递送机制以及改进分析技术以控制杂质谱），从而维持涵盖多种适应症的研发管线。合作模式十分普遍，寡核苷酸专家、合约研发生产机构和大型製药公司之间的联盟有助于获得后期研发能力和全球商业化管道。智慧财产权问题依然至关重要，推动着选择性授权和交叉授权合约的达成，这些协议决定了谁可以主导特定的偶联设计和生产流程。

为整合平台创新、监管合规、供应链韧性和商业化规划以创造永续价值，提供切实可行的建议。

寻求可持续竞争优势的产业领导者应采取将科学创新与务实的产业计画和相关人员参与相结合的策略。首先，应优先投资于偶联化学和製程开发等平台层面，以确保其能够柔软性适应多种适应症，并降低规模化生产过程中的技术风险。同时，延迟生产环节的考量可能会在后续研发阶段造成瓶颈，因此，同步投资于可扩展的合成和纯化能力对于维持专案进度和品质标准至关重要。

本研究采用稳健的混合方法研究途径，结合文献综述、监管审查、临床註册分析和专家访谈，以期从检验的证据中得出结论。

本分析所依据的研究包括对同行评审文献、监管指导文件、临床检验註册库和上市公司披露资讯的系统性回顾，以及结构化的专家访谈，以验证新出现的主题并填补知识空白。主要资料收集工作包括与临床医生、监管专家、生产专家和商业负责人进行深入讨论，以揭示有关製剂选择、给药物流和支付方证据要求等方面的实际考虑。次要资讯则用于记录与 GalNAc 连接的寡核苷酸疗法相关的技术趋势、临床结果和政策发展。

一份简洁而前瞻性的结论，整合了决定 GalNAc-siRNA 开发专案成败的技术、监管和商业性因素。

总之，基于配体设计、生产能力和不断累积的临床证据的进步，GalNAc-siRNA偶联物是一种成熟的递送方法，在多种肝臟疾病和全身性疾病中具有明确的转化应用潜力。此治疗方法的发展轨迹受到多种相互关联的因素的影响：技术优化旨在提高疗效和可生产性；不断变化的监管机构和支付方期望要求提供严格的长期证据；以及优先考虑供应链韧性和区域性准入策略的商业性需求。这些因素共同促使研发人员采用平台导向策略，整合科学创新、生产前瞻性和相关人员参与。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. GalNAc-siRNA偶联物市场（依产品类型划分）

  • 双触角
  • 单天线
  • 三触角

9. GalNAc-siRNA偶联物市场（依适应症划分）

  • 急性肝臟紫质症
  • 遗传性高胆固醇症
  • 原发性高草酸尿症1型
  • 转甲状腺素蛋白介导的类淀粉沉积症

10. GalNAc-siRNA偶联物市场（按製剂类型划分）

  • 冻干粉
  • 解决方案

第十一章 GalNAc-siRNA 偶联物市场（按最终用户划分）

  • 医院
  • 研究所
  • 专科诊所

12. GalNAc-siRNA偶联物市场依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 GalNAc-siRNA 偶联物市场：按地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. GalNAc-siRNA偶联物市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国 GalNAc-siRNA 偶联物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国 GalNAc-siRNA 偶联物市场

17. 中国的 GalNAc-siRNA 偶联物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CureVac NV
  • Dicerna Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Development Center Americas, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A3806951833

The GalNAc-siRNA Conjugates Market was valued at USD 671.21 million in 2025 and is projected to grow to USD 729.96 million in 2026, with a CAGR of 7.38%, reaching USD 1,105.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 671.21 million
Estimated Year [2026] USD 729.96 million
Forecast Year [2032] USD 1,105.37 million
CAGR (%) 7.38%

A clear and authoritative introduction that situates GalNAc-siRNA therapeutics within evolving delivery, clinical validation, and commercialization frameworks

GalNAc-conjugated small interfering RNA (siRNA) therapeutics have emerged as a defining innovation in targeted liver-directed gene silencing, integrating advances in oligonucleotide chemistry, delivery technologies, and clinical translational frameworks. Over the past decade, optimization of N-acetylgalactosamine ligands has enabled selective uptake through the asialoglycoprotein receptor on hepatocytes, substantially improving potency and safety profiles relative to earlier systemic oligonucleotide approaches. As a result, GalNAc-siRNA platforms now serve as a foundational modality for addressing hepatic and systemic disorders where reduction of pathogenic protein expression confers therapeutic benefit.

This introduction situates the modality within the broader therapeutic ecosystem by describing how improvements in conjugation architecture, linker chemistry, and manufacturing processes have aligned with clinical validation to reduce barriers to adoption. In particular, clinical programs targeting genetically mediated and metabolic conditions have demonstrated meaningful biomarker and clinical responses, thereby attracting biopharmaceutical investment and strategic collaborations. Consequently, stakeholders across discovery, clinical development, and commercialization are recalibrating priorities to leverage GalNAc conjugation for both first-in-class and follow-on indications.

To contextualize this evolution, the discussion proceeds by examining how shifts in regulatory expectations, payer considerations, and supply chain resilience intersect with technological maturation. This framing prepares readers to evaluate downstream sections that explore transformative shifts, tariff-related headwinds, segmentation nuances, regional dynamics, competitive positioning, recommended actions for leaders, and the research approach underpinning the analysis.

A comprehensive exploration of the major transformative shifts reshaping GalNAc-siRNA innovation across technology, clinical validation, and commercial strategy

The landscape for GalNAc-siRNA therapeutics is undergoing transformative shifts driven by technical maturity, expanding clinical proof points, and evolving commercial models. Advances in ligand architecture have moved beyond single paradigms, enabling developers to fine-tune valency and conjugation chemistries for enhanced hepatocyte specificity and intracellular release. Simultaneously, improvements in manufacturing-such as scalable oligonucleotide synthesis and robust purification workflows-are lowering practical barriers to multi-asset development and enabling more predictable quality attributes across clinical and commercial batches.

Concurrently, the clinical environment is shifting as late-phase data clarify long-term safety and durability, prompting payers and clinicians to re-evaluate value frameworks for durable gene-silencing interventions. As a result, commercial strategies are evolving to include outcome-based contracting, risk-sharing models, and lifecycle planning that integrates combination approaches with small molecules or biologics. Moreover, the competitive landscape is seeing increased vertical integration, with larger biotechnology and pharmaceutical companies investing in in-house nucleic acid capabilities or securing strategic partnerships to accelerate pipeline diversification.

Regulatory pathways are also adapting to the modality's unique features, with agencies emphasizing robust analytical comparability, long-term follow-up, and manufacturing control strategies that mitigate immunogenicity and off-target risks. Together, these dynamics are reshaping developer priorities from isolated asset advancement toward platform-level optimization, enabling faster translation of novel indications while maintaining rigorous safety and quality oversight.

A detailed analysis of how the cumulative impact of recent United States tariff adjustments reshaped supply chain resilience, procurement, and program cost structures for developers

The policy environment influencing global biopharmaceutical supply chains is increasingly consequential for development and commercialization timelines, as recent trade actions and tariff adjustments in the United States have introduced incremental cost pressures for certain inputs and finished goods. Tariff-related policy changes in 2025 altered the economics of sourcing raw materials, reagents, and specialized components used in oligonucleotide synthesis and conjugation processes, which necessitated rapid reassessment of procurement strategies and supplier diversification. These changes had cascading effects on manufacturers that rely on cross-border supply chains, prompting some to accelerate qualification of alternative suppliers or onshore critical manufacturing steps to reduce exposure.

In response to these pressures, companies intensified efforts to build buffer stocks of long-lead materials, renegotiate supplier contracts to include tariff contingency clauses, and evaluate manufacturing footprint adjustments. While re-shoring or near-shoring can mitigate tariff exposure over time, such shifts require capital investment and regulatory approvals, meaning the operational response must be staged and prioritized. Importantly, the tariff environment also influenced partnership negotiations, as cost assumptions embedded in collaboration agreements were revisited to reflect higher logistics and input costs.

From a strategic perspective, the cumulative impact prompted more rigorous scenario planning across development portfolios, with finance and procurement teams integrating tariff scenarios into risk assessments. Developers that proactively diversified supplier networks, invested in regional manufacturing redundancy, and optimized batch yields were better positioned to absorb short-term cost variations. As the industry moves forward, maintaining visibility across the global supply chain and engaging in active policy monitoring will remain essential for aligning development timelines with commercial readiness.

Key segmentation insights revealing how product architecture, clinical targets, care settings, distribution methods, and formulation choices interact to shape development and adoption

Insight into segmentation illuminates where scientific opportunity and commercial demand intersect across product architecture, clinical targets, care settings, distribution pathways, and formulation choices. In terms of product type, differences among biantennary, monoantennary, and triantennary conjugates frame trade-offs between receptor avidity, endosomal escape efficiency, and manufacturability, so developers are calibrating valency decisions to balance potency with downstream process complexity. Regarding indication focus, clinical programs targeting Acute Hepatic Porphyria, Homozygous Familial Hypercholesterolemia, Primary Hyperoxaluria Type 1, and Transthyretin-Mediated Amyloidosis highlight distinct development pathways: rare genetic conditions often necessitate accelerated regulatory engagement and outcome-based pricing discussions, whereas programs addressing more prevalent lipid disorders require robust comparative-effectiveness evidence and broad clinician education.

End-user segmentation reveals that hospitals, research organizations, and specialty clinics present differentiated channels for clinical adoption and commercialization, with hospitals and specialty clinics serving as primary settings for administration and monitoring, while research organizations continue to drive early translational breakthroughs and biomarker validation. Distribution channel considerations-spanning hospital pharmacies, online pharmacies, and retail pharmacies-inform patient access strategies, adherence support models, and reimbursement interactions, and underscore the importance of cold-chain logistics and specialty pharmacy integration for parenteral oligonucleotide therapies. Formulation choices between lyophilized powder and solution further influence storage, handling, and administration workflows; lyophilized formats can improve stability and shipping resilience but necessitate reconstitution protocols, whereas solution forms may simplify dispensing but place higher demands on cold-chain integrity.

Taken together, these segmentation lenses provide a multidimensional understanding of technical constraints, clinical pathways, and commercial requirements, enabling companies to prioritize development investments that align platform capabilities with the distinct needs of each therapeutic niche and care delivery channel.

Comprehensive regional insights explaining how geographical differences in regulation, payer systems, clinical trial capacity, and manufacturing shape commercialization strategies

Regional dynamics exert a powerful influence on clinical development pathways, regulatory interactions, and commercial access strategies, with distinct characteristics evident across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a concentration of clinical trial infrastructure, payer innovation, and investor capital accelerates late-stage development and enables diverse commercialization models, yet reimbursement negotiations and regional procurement practices demand rigorous health-economic evidence and real-world outcome data. By contrast, the Europe, Middle East & Africa region presents a heterogeneous regulatory and payer landscape, where coordinated European regulatory pathways are balanced against country-specific health technology assessment processes and variable access in emerging markets, encouraging tailored market entry and pricing strategies.

Asia-Pacific offers a complex mix of mature markets with advanced regulatory frameworks and rapidly developing economies with expanding clinical trial capacity; this region is increasingly important for enrollment efficiency, cost-effective manufacturing, and regional partnerships that support broader market reach. Across all regions, localized considerations-such as genetic epidemiology, healthcare infrastructure, and specialty care access-inform indication prioritization and post-approval evidence generation strategies. Moreover, supply chain resiliency and regional manufacturing capabilities are becoming central to planning, as companies seek to ensure consistent product availability while meeting diverse regulatory quality expectations.

Consequently, commercial leaders are adopting region-specific playbooks that integrate clinical development timing, regulatory engagement plans, and payer evidence generation tailored to the operational realities of each geography, thereby enabling more predictable adoption pathways and sustainable market access.

Critical company-level insights that highlight platform development, partnership models, manufacturing preparedness, and regulatory engagement as differentiators in the GalNAc-siRNA competitive landscape

Competitive dynamics among companies developing GalNAc-siRNA therapeutics reflect a balance of platform expertise, clinical execution, and strategic partnerships. Leading developers are investing in platform robustness-optimizing conjugation chemistries, enhancing intracellular delivery mechanisms, and refining analytics for impurity profile control-to sustain pipelines across multiple indications. Collaboration models are prevalent, with alliances between oligonucleotide specialists, contract development and manufacturing organizations, and larger pharmaceutical partners facilitating access to late-stage development capabilities and global commercial channels. Intellectual property considerations remain central, driving selective licensing and cross-licensing arrangements that shape who can advance particular conjugation designs or manufacturing workflows.

Operational excellence in clinical development differentiates companies that can rapidly translate preclinical promise into convincing clinical endpoints while navigating safety monitoring and long-term follow-up requirements. Firms that prioritize scalable manufacturing early in the development cycle reduce technical uncertainty and shorten time-to-clinic. In parallel, those who proactively engage with regulators and payers to define acceptable evidence packages and value propositions are better positioned to secure earlier and broader patient access. Finally, organizational capabilities such as integrated regulatory affairs, medical affairs, and market access functions enable coherent positioning of novel therapeutics in complex therapeutic landscapes, thereby increasing the likelihood of successful commercialization and sustained adoption.

Actionable recommendations for leaders to synchronize platform innovation, regulatory engagement, supply chain resilience, and commercialization planning to capture sustainable value

Industry leaders seeking durable advantage should adopt integrated strategies that align scientific innovation with pragmatic operational planning and stakeholder engagement. First, prioritize platform-level investments in conjugation chemistry and process development to ensure the flexibility required for multiple indications and to reduce technical risk during scale-up. By contrast, delaying manufacturing considerations can create bottlenecks later in development, so parallel investment in scalable synthesis and purification capabilities is essential to maintain program timelines and quality standards.

Secondly, cultivate robust regulatory and payer engagement strategies early in development. Proactively share data with regulators to clarify expectations for long-term safety monitoring and analytical comparability, and initiate payer conversations to identify evidence thresholds for reimbursement. Third, diversify supply chains geographically and qualify alternate suppliers for critical reagents to hedge against tariff volatility and logistical disruptions. In addition, establish regional manufacturing partnerships where feasible to expedite market entry and enhance supply security.

Finally, embed commercial foresight into development programs by mapping end-user workflows and distribution channel requirements into product design and packaging decisions. Consider formulation trade-offs that minimize administration complexity for hospital and specialty clinic settings while optimizing distribution partners such as hospital pharmacies and specialty pharmacies to ensure patient-centric access. Executing these measures in tandem will strengthen resilience, accelerate adoption, and enhance long-term value capture.

A robust mixed-methods research approach combining literature synthesis, regulatory review, clinical registry analysis, and expert interviews to ground the findings in validated evidence

The research underpinning this analysis combined systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly disclosed company filings with structured expert interviews to validate emergent themes and fill knowledge gaps. Primary data collection involved in-depth discussions with clinicians, regulatory experts, manufacturing specialists, and commercial leaders to surface practical considerations around formulation choices, delivery logistics, and payer evidence needs. Secondary sources were synthesized to document technological trajectories, clinical outcomes, and policy developments relevant to GalNAc-conjugated oligonucleotide therapeutics.

Analytical methods included cross-sectional comparison of clinical program design elements, assessment of manufacturing and supply chain capabilities, and thematic coding of interview insights to identify common barriers and enablers. Quality assurance steps ensured that findings were corroborated across multiple data sources and that any conflicting perspectives were transparently represented. Throughout the research process, attention was paid to geographic variation in regulatory practices and healthcare delivery systems to ensure that regional insights reflected operational realities faced by developers and payers alike.

This mixed-methods approach provided both breadth and depth, enabling robust interpretation of technological trends, competitive positioning, and strategic implications without relying on proprietary market sizing, thereby equipping stakeholders with actionable intelligence for decision-making.

A concise and forward-looking conclusion synthesizing technological, regulatory, and commercial imperatives that determine success for GalNAc-siRNA development programs

In conclusion, GalNAc-siRNA conjugates represent a matured delivery approach with clear translational potential across a range of hepatic and systemic disorders, grounded in advances in ligand design, manufacturing capability, and accumulating clinical evidence. The modality's trajectory is shaped by interconnected forces: technical optimization that improves potency and manufacturability, evolving regulatory and payer expectations that demand rigorous long-term evidence, and commercial imperatives that prioritize supply chain resilience and region-specific access strategies. Together, these factors compel developers to adopt platform-minded strategies that integrate scientific innovation with manufacturing foresight and stakeholder engagement.

Looking ahead, success will favor organizations that can harmonize early-stage translational work with pragmatic operational execution-those that invest in scalable processes, engage regulators and payers proactively, and tailor regional approaches to reflect local regulatory and healthcare delivery nuances. By following these principles, developers and investors can translate therapeutic promise into meaningful clinical impact while navigating policy and commercial headwinds.

Ultimately, the insights presented here are intended to inform strategic choices and catalyze action among researchers, executives, and investors seeking to participate in the next phase of oligonucleotide innovation, ensuring that scientific advances are matched by disciplined execution and stakeholder alignment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GalNAc-siRNA Conjugates Market, by Product Type

  • 8.1. Biantennary
  • 8.2. Monoantennary
  • 8.3. Triantennary

9. GalNAc-siRNA Conjugates Market, by Indication

  • 9.1. Acute Hepatic Porphyria
  • 9.2. Homozygous Familial Hypercholesterolemia
  • 9.3. Primary Hyperoxaluria Type 1
  • 9.4. Transthyretin-Mediated Amyloidosis

10. GalNAc-siRNA Conjugates Market, by Formulation

  • 10.1. Lyophilized Powder
  • 10.2. Solution

11. GalNAc-siRNA Conjugates Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Organizations
  • 11.3. Specialty Clinics

12. GalNAc-siRNA Conjugates Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. GalNAc-siRNA Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. GalNAc-siRNA Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. GalNAc-siRNA Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States GalNAc-siRNA Conjugates Market

17. China GalNAc-siRNA Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Akcea Therapeutics, Inc.
  • 18.6. Alnylam Pharmaceuticals, Inc.
  • 18.7. Amgen Inc.
  • 18.8. Arcturus Therapeutics Holdings Inc.
  • 18.9. Arrowhead Pharmaceuticals, Inc.
  • 18.10. AstraZeneca plc
  • 18.11. Bayer AG
  • 18.12. Beam Therapeutics Inc.
  • 18.13. BioNTech SE
  • 18.14. CureVac N.V.
  • 18.15. Dicerna Pharmaceuticals, Inc.
  • 18.16. Eli Lilly and Company
  • 18.17. Gilead Sciences, Inc.
  • 18.18. GlaxoSmithKline plc
  • 18.19. Ionis Pharmaceuticals, Inc.
  • 18.20. Merck & Co., Inc.
  • 18.21. Moderna, Inc.
  • 18.22. Novartis AG
  • 18.23. Novo Nordisk A/S
  • 18.24. Pfizer Inc.
  • 18.25. Roche Holding AG
  • 18.26. Sanofi S.A.
  • 18.27. Sarepta Therapeutics, Inc.
  • 18.28. Takeda Development Center Americas, Inc.
  • 18.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GALNAC-SIRNA CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY BIANTENNARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY BIANTENNARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY BIANTENNARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY MONOANTENNARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY MONOANTENNARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY MONOANTENNARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRIANTENNARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRIANTENNARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRIANTENNARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ACUTE HEPATIC PORPHYRIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ACUTE HEPATIC PORPHYRIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ACUTE HEPATIC PORPHYRIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRIMARY HYPEROXALURIA TYPE 1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRIMARY HYPEROXALURIA TYPE 1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRIMARY HYPEROXALURIA TYPE 1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. G7 GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 136. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. NATO GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GALNAC-SIRNA CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA GALNAC-SIRNA CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)